Caxton Associates (New York)’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Caxton Associates (New York)’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-9,049	Closed	-$434K	–	691
2020 Q1	$434K	Buy	+9,049	New	+$421K	0.08%	185

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Caxton Associates (New York)'s RARX Position: Q2 2020 in Review

Caxton Associates (New York) sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 9,049 shares — an estimated $434K sold.

Caxton Associates (New York) first reported a position in RARX in Q1 2020 and held it in 1 quarter. The position peaked at $434K in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Caxton Associates (New York) reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Caxton Associates (New York) sold 9,049 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $434K.
Caxton Associates (New York) first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
Caxton Associates (New York)'s Ra Pharmaceuticals, Inc. Common Stock position peaked at $434K in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.